Atlantic Healthcare completed enrollment in its Phase 3 study of alicaforsen for patients with IBD pouchitis. Here are five things to know. 1. IBD pouchitis is a severe form of irritable bowel disease ...
"Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, reports a study. "Pouchitis" developing ...
The objectives of the FILLMORE trial were to assess the safety and efficacy of AMT-101 in severe chronic pouchitis patients and to select a dose for Phase 3. The trial was designed to measure two key ...
Met primary endpoint of safety: MH002 was safe and well tolerated with no evidence of adverse reactions when administered for 8 weeks. Clinical remission rate of 46% at week 8, a mean decrease in the ...
Please provide your email address to receive an email when new articles are posted on . Atlantic Healthcare has completed enrollment for a phase 3 trial of the efficacy and safety of alicaforsen, a ...
GHENT, Belgium--(BUSINESS WIRE)--MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Fruit consumption may have a protective effect against intestinal inflammation in inflammatory bowel ...
Obesity at ages 7 to 8 years was associated with increased ulcerative colitis (UC) risk in a Scandinavian cohort. (Inflammatory Bowel Diseases) The safety and effectiveness of combining biologics and ...
Philadelphia, Pa. (October 10, 2013) –"Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback